Elitecon International Limited has published its unaudited financial results for the quarter and nine months ended December 31, 2025, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted copies of publication advertisements to stock exchanges on March 10, 2026, following the Board meeting held on March 07, 2026.

Regulatory Compliance and Publication

The company fulfilled its regulatory obligations under Regulation 30 read with Regulation 47 of SEBI LODR by publishing advertisements on March 10, 2026, in all editions of 'Financial Express' (English Language) and the Delhi Edition of 'Jansatta' (Hindi). These publications are also available on the company's website at www.eliteconinternational.com .

Standalone Financial Performance

The company's standalone operations demonstrated exceptional growth in Q3FY26. Revenue from operations increased substantially while maintaining strong profitability metrics despite challenging market conditions.

For the nine months ended December 31, 2025, standalone revenue reached ₹120,684.95 lakhs compared to ₹17,709.73 lakhs in the corresponding previous period. Net profit for the nine-month period stood at ₹5,012.02 lakhs versus ₹1,999.89 lakhs in the previous year.

Consolidated Results

The consolidated financial performance showed even stronger growth, reflecting the company's expanded operations through subsidiaries and strategic acquisitions.

The nine-month consolidated revenue reached ₹547,688.65 lakhs compared to ₹23,559.70 lakhs in the previous year, while consolidated net profit increased to ₹31,116.69 lakhs from ₹2,667.60 lakhs.

Segment Performance Analysis

Elitecon International operates through two primary business segments: Tobacco Products and FMCG Products. Both segments contributed significantly to the overall growth during the quarter.

Standalone Segment Results (Q3FY26)

Consolidated Segment Results (Q3FY26)

Corporate Actions and Strategic Developments

During the nine months ended December 31, 2025, the company completed a subdivision of its equity shares from ₹10 each to ₹1 each. The subdivision received member approval through an ordinary resolution passed on June 2, 2025, with necessary regulatory approvals obtained.

The company entered into Share Purchase Agreements dated September 4, 2025, for acquiring equity stakes in Sunbridge Agro Private Limited and Landsmill Agro Private Limited. While partial consideration has been discharged, the balance consideration was proposed to be funded through a Qualified Institutional Placement (QIP), which could not be concluded.

Regulatory and Legal Matters

Elitecon International continues to address several ongoing regulatory challenges:

GST Matters: The company is addressing a Show Cause Notice dated May 9, 2025, issued by the Directorate General of GST Intelligence (DGGI) regarding input tax credit for the period from October 2020 to October 2024. A personal hearing was attended on February 4, 2026, with no adjudication order passed yet.

FDA Inspection: Subsequent to the quarter end, officials from the Food and Drug Administration (FDA), Nashik, conducted inspections at the company's manufacturing facility on January 8, 2026, and at subsidiary Golden Cryo Private Limited on January 9, 2026. Certain tobacco product inventories and related machinery were seized during these inspections.

Legal Proceedings: The company is involved in legal proceedings with Advik Capital Limited, with matters pending before the High Court of Delhi and the National Company Law Tribunal (NCLT). The company is contesting these matters and taking appropriate legal steps.

Financial Position and Outlook

The company's paid-up equity share capital stands at ₹15,985.00 lakhs with a face value of ₹1 per share. The substantial revenue growth reflects the company's expanded operations and successful business diversification across tobacco and FMCG segments.

Management continues to evaluate the financial implications of regulatory actions and is working on resolving pending matters while maintaining normal business operations across other segments.

Elitecon International has provided detailed disclosure regarding the Food and Drug Administration inspection at its manufacturing facility in Nashik, Maharashtra. The inspection, conducted on January 08, 2026, resulted in seizure of inventories and equipment, with the company formally disclosing the matter on March 02, 2026.

Inspection and Seizure Details

FDA officials from Nashik, Maharashtra conducted the inspection at the company's manufacturing facility located at GAT Number 353/2 Mauje Talegaon, Dindori Nashik Maharashtra. The inspection was carried out pursuant to a Government of Maharashtra notification dated July 20, 2025, issued under the Food Safety and Standards Act, 2006.

Regulatory Compliance and Allegations

The alleged contravention relates to the manufacture and storage of products covered under the Government of Maharashtra notification for tobacco products. During the inspection, certain inventories of tobacco products along with related packing and sealing machines were seized by the authorities. The matter is currently under review before the appropriate authorities.

Delayed Disclosure Explanation

Elitecon International disclosed the inspection details on March 02, 2026, nearly two months after the incident. The company clarified that the delay in disclosure was unintentional and occurred during the process of verification of facts and legal evaluation of the matter. The company expressed sincere regret for the delay and committed to ensuring timely and appropriate disclosures in the future.

Business Impact Assessment

The company has stated that its other business operations continue in the normal course with no material impact on overall operations or going concern status. However, the financial, operational, or other impact of this regulatory matter cannot be ascertained or quantified in monetary terms at this time.

Corporate Governance Commitment

Elitecon International reaffirmed its commitment to comply with all applicable laws, rules, regulations, circulars, and guidelines. The company emphasized that all its actions are carried out in good faith, with transparency, and in accordance with established corporate governance standards. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.